Last updated: November 10, 2026
Epirubicin hydrochloride is an established generic anthracycline used mainly in breast cancer and selected bladder, gastric, lymphoma, sarcoma, and other oncology protocols. Its commercial profile is defined by low unit pricing, hospital procurement, generic competition, supply reliability, and clinical substitution rather than patent exclusivity. The originator product, Ellence, no longer has meaningful U.S. market protection, and no biosimilar pathway applies because epirubicin is a small-molecule drug. Public financial reporting does not disclose standalone epirubicin revenue.
What is epirubicin hydrochloride and how is it used?
Epirubicin hydrochloride is the hydrochloride salt of epirubicin, an anthracycline cytotoxic agent. It intercalates DNA and inhibits topoisomerase II, producing antitumor activity but also dose-limiting cardiotoxicity and myelosuppression.
The drug is administered intravenously. Its principal labeled U.S. indication is adjuvant therapy for patients with evidence of axillary-node tumor involvement after resection of primary breast cancer, usually as part of combination chemotherapy [1].
Outside the United States, epirubicin has broader historical use in:
- Breast cancer
- Non-muscle-invasive and muscle-invasive bladder cancer
- Gastric cancer
- Ovarian cancer
- Lymphomas
- Soft-tissue sarcoma
- Other solid tumors under national or institutional protocols
Epirubicin is commonly compared with doxorubicin. It has a broadly similar anthracycline mechanism, while clinical use depends on cumulative dose, regimen design, toxicity profile, local guidelines, and formulary economics.
What is the FDA regulatory status of epirubicin hydrochloride?
The FDA approved Ellence, epirubicin hydrochloride injection, under NDA 050718 in 1999. Pharmacia & Upjohn was the original U.S. sponsor. The product is supplied as an intravenous injection in multiple strengths, including 50 mg/25 mL and 200 mg/100 mL presentations in commonly referenced labeling [1, 2].
The regulatory position is mature:
| Regulatory item |
Status |
| Active ingredient |
Epirubicin hydrochloride |
| Dosage form |
Intravenous injection |
| Drug class |
Anthracycline antineoplastic |
| Original U.S. brand |
Ellence |
| Original U.S. approval |
1999 |
| U.S. approval holder historically associated with brand |
Pharmacia & Upjohn |
| Main U.S. indication |
Adjuvant therapy for node-positive breast cancer |
| Prescription status |
Prescription oncology drug |
| Biosimilar pathway |
Not applicable |
| Market structure |
Generic and institutional procurement driven |
The U.S. label carries boxed warnings for cardiomyopathy, secondary malignancies, extravasation injury, severe myelosuppression, and other serious toxicities [1].
When did epirubicin lose exclusivity?
Epirubicin lost practical exclusivity years ago. The product is now a mature generic oncology medicine, and commercial access is determined primarily by abbreviated new drug applications, manufacturing capacity, hospital contracts, and national reimbursement systems.
FDA exclusivity periods associated with the original product have expired. Any historical patents linked to the innovator product are also beyond their enforceable commercial life for ordinary generic-entry purposes. The current market does not depend on an active composition-of-matter patent.
The key commercial distinction is between regulatory exclusivity and supply-chain access:
- Regulatory exclusivity is no longer a material barrier.
- Generic approval is available through the ANDA pathway.
- Hospital and group-purchasing contracts can still affect market access.
- Manufacturing interruptions can create temporary pricing power.
- Product quality, sterile manufacturing capacity, and injectable supply reliability are more important than patent ownership.
What patents protect epirubicin hydrochloride?
No active, commercially meaningful U.S. patent estate is generally associated with the mature epirubicin hydrochloride market. The original product’s protection was based on historical anthracycline chemistry and product-related rights that have expired or ceased to constrain ordinary generic entry.
The relevant intellectual-property categories are:
| Patent category |
Current commercial relevance |
| Active ingredient or composition patents |
No material barrier identified for standard epirubicin hydrochloride |
| Salt-form patents |
No material barrier for routine generic supply |
| Injectable formulation patents |
Potentially relevant only to a specific protected formulation, if any |
| Method-of-use patents |
Limited relevance where treatment protocols are established and generic labeling differs |
| Manufacturing-process patents |
May protect a supplier’s process but generally do not block all generic production |
| Drug-delivery patents |
Relevant only to specialized liposomal, nanoparticle, or combination products |
A supplier can maintain confidential know-how covering impurity control, crystallization, sterilization, vial filling, stability, and scale-up. Those trade secrets can create operational advantages without creating broad market exclusivity.
What is the Orange Book status of epirubicin hydrochloride?
The Orange Book is relevant to the U.S. reference product, Ellence, and any approved generic products with therapeutic-equivalence determinations. Because the product is old and genericized, the Orange Book is not expected to show an unexpired patent listing that materially delays entry for standard epirubicin hydrochloride injection.
The commercial implications are:
- Generic applicants do not face a current composition patent barrier.
- Paragraph IV litigation is not a central market event.
- A later entrant would usually compete on approval status, price, supply, and contracting.
- Any patent dispute would more likely concern a specialized formulation, manufacturing method, or delivery technology than conventional epirubicin injection.
The Orange Book’s TE code and applicant listings remain relevant for procurement decisions, but therapeutic equivalence does not guarantee identical vial sizes, preservatives, packaging, or institutional handling characteristics.
Are there Paragraph IV challenges involving epirubicin?
Paragraph IV challenges are not a meaningful current driver for standard epirubicin hydrochloride. Paragraph IV certifications are most commercially significant when an ANDA applicant challenges listed, unexpired patents. Epirubicin’s conventional injectable market is too mature for ordinary patent litigation to define entry timing.
The more relevant entry routes are:
- Paragraph III certification against expired patents
- No-patent certification
- ANDA approval based on a mature reference product
- Market entry after manufacturing and inspection readiness
- Product launch following supply-contract awards
A generic applicant can still face regulatory delay from deficiencies, facility inspections, stability data, extractables and leachables, or sterile manufacturing controls. Those issues are operational rather than patent-based.
What formulations are protected by epirubicin patents?
The commercially established formulation is an aqueous intravenous epirubicin hydrochloride injection. Its value is concentrated in sterile manufacturing, concentration control, vial presentation, storage stability, and safe handling.
Specialized formulations may create separate intellectual-property opportunities:
Liposomal epirubicin
Liposomal delivery can seek to alter tissue distribution, tolerability, or pharmacokinetics. A liposomal product would likely require separate clinical and regulatory support rather than relying on a conventional injectable generic pathway.
Nanoparticle or targeted formulations
Nanoparticle systems, antibody-linked delivery, and tumor-targeted formulations could generate new patent claims covering composition, particle size, targeting ligands, release profiles, or treatment methods. These products would compete in a different value segment from standard epirubicin.
Combination products
Patents may cover fixed or co-formulated combinations with other oncology agents. Combination claims face technical and regulatory hurdles because clinical benefit, compatibility, dosing, and manufacturing consistency must be demonstrated.
No specialized epirubicin formulation has displaced the conventional injection as the primary commercial product in the mature generic market.
Which companies compete in the epirubicin hydrochloride market?
Competition is fragmented and varies by country. Manufacturers and suppliers can include multinational generic companies, specialty injectable manufacturers, regional oncology suppliers, and contract manufacturers. The exact supplier roster changes because hospital tenders, discontinuations, shortages, and licensing arrangements alter national availability.
The competitive set includes:
- Generic injectable oncology manufacturers
- Hospital-focused sterile injectables companies
- Regional suppliers in Europe, Asia, and Latin America
- Contract development and manufacturing organizations
- Distributors purchasing through public and private tenders
Epirubicin also competes therapeutically with:
- Doxorubicin
- Liposomal doxorubicin
- Mitoxantrone in selected settings
- Taxane-based combinations
- Cyclophosphamide-containing regimens
- Targeted breast cancer therapies
- Immunotherapies and antibody-drug conjugates in eligible patients
The strongest competitive pressure comes from treatment substitution. In breast cancer, anthracycline use has declined in some segments as clinicians adopt risk-adapted regimens, genomic testing, HER2-directed therapy, taxanes, and other targeted agents.
How does epirubicin compare with doxorubicin?
| Factor |
Epirubicin |
Doxorubicin |
| Drug class |
Anthracycline |
Anthracycline |
| Administration |
Intravenous |
Intravenous |
| U.S. brand history |
Ellence |
Adriamycin |
| Generic availability |
Broad and mature |
Broad and mature |
| Main commercial use |
Breast cancer and international oncology protocols |
Broad solid-tumor and hematologic use |
| Cardiotoxicity concern |
Material |
Material |
| Patent-driven pricing |
No meaningful current protection |
No meaningful current protection |
| Competitive position |
Protocol and formulary dependent |
More widely embedded in global protocols |
| Main differentiation |
Regimen selection and clinical familiarity |
Breadth of indications and long clinical history |
Epirubicin has historically been used where clinicians seek an anthracycline option with a different dose-intensity or toxicity profile. The distinction does not create substantial pricing power in a generic hospital market.
What is the financial trajectory of epirubicin hydrochloride?
Epirubicin’s financial trajectory is mature-to-declining in value terms, with intermittent volume resilience. Public companies generally do not report epirubicin revenue separately because sales are aggregated into oncology, hospital injectables, or established pharmaceutical portfolios.
The likely revenue pattern is:
| Period |
Financial profile |
| Original launch period |
Premium branded oncology pricing |
| Generic-entry period |
Rapid price erosion and supplier expansion |
| Mature generic period |
Low unit pricing, tender-driven revenue |
| Current market |
Stable clinical demand with limited pricing power |
| Supply disruption periods |
Temporary price increases or allocation gains |
| Long-term outlook |
Volume retention in selected protocols, value pressure from substitution |
Revenue exposure is more meaningful for manufacturers with a large sterile-injectable portfolio than for companies with a single epirubicin product. A supplier may benefit from:
- Multi-year hospital tenders
- National reimbursement inclusion
- Scarcity of qualified sterile-injectable capacity
- Portfolio bundling with other oncology medicines
- Geographic markets with limited local competition
The main financial risks are generic price compression, tender losses, raw-material shortages, manufacturing observations, product recalls, and declining anthracycline use in selected breast cancer populations.
What patent litigation affects epirubicin?
No major ongoing U.S. patent litigation is central to the conventional epirubicin hydrochloride injection market. Litigation risk is low relative to newer oncology drugs because:
- The active ingredient is long established.
- Generic entry has already occurred.
- There is no apparent blocking composition patent.
- The product is not a biologic.
- Market pricing limits the economic incentive for extensive litigation.
Potential disputes could still arise over:
- ANDA product quality
- Trade dress and packaging
- Manufacturing processes
- Contract rights
- Supply agreements
- Specialized delivery technologies
- False advertising or therapeutic-equivalence claims
These disputes would generally have limited effect on the broad market unless they involved a major supplier or a product shortage.
What generic launch scenarios exist for epirubicin?
A conventional generic launch does not require a major patent settlement. The principal scenarios are:
Low-price tender launch
A new supplier enters through a national or hospital tender and wins volume with aggressive pricing. This can reduce incumbent share quickly but may compress margins across the category.
Supply-constrained launch
A supplier enters when incumbent manufacturers face shortages, plant closures, or regulatory restrictions. Market share can expand rapidly, although the entrant must maintain reliable sterile production.
Regional launch
A company receives approval in one jurisdiction but remains commercially limited by local reimbursement, distributor access, or tender timing.
Portfolio launch
Epirubicin is introduced alongside doxorubicin, oxaliplatin, paclitaxel, or other oncology injectables. The supplier uses portfolio breadth to secure institutional contracts.
Specialized formulation launch
A liposomal or targeted epirubicin product would face greater development cost, clinical differentiation requirements, and potentially new patent protection. This would not be a conventional generic launch.
What manufacturing and geographic barriers affect epirubicin?
The principal barriers are manufacturing and procurement related. Sterile oncology production requires validated aseptic processing, containment systems, operator protection, environmental controls, and reliable quality systems.
Geographic market conditions differ:
| Region |
Market characteristics |
| United States |
Mature generic market, hospital purchasing, FDA quality oversight |
| European Union |
National reimbursement and hospital tenders, multiple suppliers |
| China |
Large oncology demand, domestic manufacturing and centralized procurement influence |
| India |
Strong generic manufacturing base and export orientation |
| Latin America |
Country-specific registration, public procurement, distributor dependence |
| Middle East and Africa |
Import reliance and supply continuity are important |
Epirubicin is hazardous to handle, which raises operational requirements for production, pharmacy preparation, and waste disposal. Those requirements can reduce the number of qualified suppliers even when patents no longer limit entry.
Is epirubicin exposed to biosimilar competition?
No. Epirubicin hydrochloride is a chemically synthesized small molecule, not a biologic. Biosimilar approval standards therefore do not apply.
Its competitive risk comes from:
- Other generic anthracyclines
- Liposomal doxorubicin
- Non-anthracycline chemotherapy
- Targeted breast cancer agents
- Antibody-drug conjugates
- Immunotherapy
- Treatment de-escalation in lower-risk disease
The absence of biosimilar risk does not eliminate competitive pressure. Therapeutic substitution is more important than biosimilar entry.
How strong is the epirubicin patent estate?
The patent estate is weak from a market-exclusivity perspective and strong only in the limited sense that the drug has an established regulatory and manufacturing history.
| Dimension |
Assessment |
| Composition-of-matter protection |
Expired or commercially irrelevant |
| Regulatory exclusivity |
Expired |
| Formulation protection |
Limited for conventional injection |
| Method-of-use protection |
Limited in mature labeled indications |
| Manufacturing know-how |
Potentially valuable to individual suppliers |
| Litigation exposure |
Low |
| Generic-entry risk |
High |
| Pricing power |
Low |
| Supply-chain value |
Moderate during shortages |
| Long-term commercial moat |
Narrow |
Key Takeaways
- Epirubicin hydrochloride is a mature generic anthracycline with no meaningful current patent barrier in conventional intravenous injection.
- Ellence, the original U.S. brand, was approved in 1999 and no longer has practical exclusivity.
- The Orange Book is relevant for reference-product and generic status, but Paragraph IV litigation is not a central market issue.
- No biosimilar pathway applies because epirubicin is a small molecule.
- Financial performance is driven by hospital tenders, sterile manufacturing capacity, supply continuity, and therapeutic substitution.
- Public companies generally do not disclose standalone epirubicin revenue.
- The commercial outlook is stable in established oncology protocols but pressured by generic price erosion and newer breast cancer therapies.
- Specialized liposomal, nanoparticle, or combination formulations could create new intellectual-property value, but conventional epirubicin injection has limited patent strength.
- The main generic-entry risks are manufacturing quality, facility capacity, regulatory approval, and contract access rather than patent litigation.
FAQs
Is epirubicin hydrochloride still commercially available?
Yes. It remains available through generic oncology suppliers in multiple markets, although product availability can vary by country, tender cycle, manufacturer, and sterile-injectable supply conditions.
Does epirubicin hydrochloride have an active U.S. composition patent?
No commercially meaningful active composition patent is generally associated with conventional epirubicin hydrochloride injection.
Can a company launch generic epirubicin without settling patent litigation?
Yes. The mature product generally does not require a patent settlement for standard generic entry because the principal historical exclusivity barriers have expired.
Is epirubicin more profitable than doxorubicin?
Usually not on a unit basis. Both are mature generic anthracyclines, and profitability depends more on manufacturing cost, tender pricing, shortage conditions, and portfolio contracting than on the molecule alone.
What is the largest long-term threat to epirubicin demand?
Therapeutic substitution is the largest structural threat. Targeted breast cancer drugs, antibody-drug conjugates, immunotherapies, taxanes, and risk-adapted treatment protocols can reduce anthracycline use in selected patients.
References
-
U.S. Food and Drug Administration. (2010). Ellence (epirubicin hydrochloride) injection prescribing information. FDA.
-
DailyMed. (2024). Epirubicin hydrochloride injection. National Library of Medicine.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
National Cancer Institute. (2024). Epirubicin hydrochloride. NCI Drug Dictionary.
-
European Medicines Agency. (2024). Epirubicin-containing medicinal products and product information. EMA.